Literature DB >> 25359914

Draft Genome Sequence of Colistin-Only-Susceptible Pseudomonas aeruginosa Strain ST235, a Hypervirulent High-Risk Clone in Spain.

Esther Viedma, Jenifer Villa1, Carlos Juan, Antonio Oliver, Fernando Chaves2.   

Abstract

We report the genome of colistin-only-susceptible Pseudomonas aeruginosa strain ST235 (PA_ST235). This isolate was obtained in the setting of an outbreak in a tertiary hospital in Spain. This clone was apparently associated with a significantly higher mortality rate. The ST235 clone also appears to be associated with greater virulence.
Copyright © 2014 Viedma et al.

Entities:  

Year:  2014        PMID: 25359914      PMCID: PMC4214990          DOI: 10.1128/genomeA.01097-14

Source DB:  PubMed          Journal:  Genome Announc


GENOME ANNOUNCEMENT

Pseudomonas aeruginosa is an opportunistic pathogen in humans, frequently causing serious infections in immunocompromised and critically ill patients, due to its remarkable ability to combine mutation-driven and horizontally acquired resistance mechanisms (1, 2). Molecular epidemiology studies, along with a deep genetic investigation of chromosomal and transferable resistance mechanisms, allowed us to describe a highly spread clone ST235 of colistin-only-susceptible (COS) P. aeruginosa, simultaneously producing the extended-spectrum β-lactamases (ESBLs) GES-1 and GES-5 in a class 1 integron in a Spanish hospital (3). The ST235 clone is considered a high-risk clone that has been reported in hospital outbreaks worldwide and associated with multidrug resistance patterns by acquisition of different ESBLs and carbapenemases (4–6). However, this clone totally disappeared in our institution and was replaced by another high-risk clone (ST175), which resulted in an endemic situation of multiresistant VIM-2-producing P. aeruginosa (7). The P. aeruginosa ST235 genome (PA_ST235) was sequenced using a Roche 454 Junior sequencer. A total of 227,356,902 bp were obtained, providing approximately 26-fold coverage and 476,129 reads. Sequences obtained were used for de novo assembly using Newbler Assembler version 3.0 (Roche). The draft genome sequence consists of 130 contigs with an N50 contig size of 191,815 nucleotides and a total length of 6,930,611 bp. Sequences were annotated using the Rapid Annotation Using Subsystem Technology (RAST) server (8). A total of 6,539 coding DNA sequence (CDS) genes and 60 tRNAs were detected. This approach highlighted the presence of up to 136 genes related to antibiotic and antiseptic resistance. The verification of the class 1 integron harboring tandem duplication of GES1/GES5, as previously reported in this clone (3), was performed with BLAST (http://www.ncbi.nlm.nih.gov/BLAST). Several chromosomal mutations and proteins involved in antibiotic and antiseptic resistance, including many of those previously reported for other lineages, were also detected (9). Furthermore, a total of 62 related phage and prophage elements were detected. The ST235 clone, besides its wide dissemination, appears to be associated with greater virulence (3, 10). PA_ST235 whole genome sequencing revealed the presence of type III secretion system cytotoxins ExoU and ExoY; in particular, ExoU has been associated with increased virulence (10). This strain was not a carrier of any plasmid as occurred with VIM-2-producing the P. aeruginosa ST175 clone (11). A genomic comparison of both clones performed with the RAST server revealed that no major differences in resistance mechanisms exist, as previously reported for each of the clones (3, 7). A few genes associated with resistance and virulence were detected in the PA_ST235 clone but not in the ST175 clone: ExoU protein, DedA protein, MacA protein (macrolide-specific efflux) or YdhE/NorM (multidrug and toxin extrusion [MATE] family efflux pump). A comprehensive genomic comparative analysis of the two clones, along with other sporadic and successful clones, might shed some hypotheses on the genetic factors determining clonal success and virulence, and thus establish new containment measures against the spread of this type of clone.

Nucleotide sequence accession number.

This whole-genome shotgun project has been deposited at DDBJ/EMBL/GenBank under the accession number JNHD00000000.
  11 in total

1.  Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact.

Authors:  Valerie Aloush; Shiri Navon-Venezia; Yardena Seigman-Igra; Shaltiel Cabili; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

2.  Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain.

Authors:  Esther Viedma; Carlos Juan; Joshi Acosta; Laura Zamorano; Joaquín R Otero; Francisca Sanz; Fernando Chaves; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191

3.  Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem.

Authors:  Elena Riera; Gabriel Cabot; Xavier Mulet; María García-Castillo; Rosa del Campo; Carlos Juan; Rafael Cantón; Antonio Oliver
Journal:  J Antimicrob Chemother       Date:  2011-06-08       Impact factor: 5.790

4.  National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002.

Authors:  Marilee D Obritsch; Douglas N Fish; Robert MacLaren; Rose Jung
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

Review 5.  Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance.

Authors:  Neil Woodford; Jane F Turton; David M Livermore
Journal:  FEMS Microbiol Rev       Date:  2011-03-01       Impact factor: 16.408

6.  Genetic markers of widespread extensively drug-resistant Pseudomonas aeruginosa high-risk clones.

Authors:  Gabriel Cabot; Alain A Ocampo-Sosa; M Angeles Domínguez; Juan F Gago; Carlos Juan; Fe Tubau; Cristina Rodríguez; Bartolomé Moyà; Carmen Peña; Luis Martínez-Martínez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2012-10-08       Impact factor: 5.191

7.  Spread of extensively resistant VIM-2-positive ST235 Pseudomonas aeruginosa in Belarus, Kazakhstan, and Russia: a longitudinal epidemiological and clinical study.

Authors:  Mikhail V Edelstein; Elena N Skleenova; Oksana V Shevchenko; Jimson W D'souza; Dmitry V Tapalski; Ilya S Azizov; Marina V Sukhorukova; Roman A Pavlukov; Roman S Kozlov; Mark A Toleman; Timothy R Walsh
Journal:  Lancet Infect Dis       Date:  2013-07-09       Impact factor: 25.071

8.  VIM-2-producing multidrug-resistant Pseudomonas aeruginosa ST175 clone, Spain.

Authors:  Esther Viedma; Carlos Juan; Jennifer Villa; Laura Barrado; M Angeles Orellana; Francisca Sanz; Joaquín R Otero; Antonio Oliver; Fernando Chaves
Journal:  Emerg Infect Dis       Date:  2012-08       Impact factor: 6.883

9.  Draft Genome Sequence of VIM-2-Producing Multidrug-Resistant Pseudomonas aeruginosa ST175, an Epidemic High-Risk Clone.

Authors:  Esther Viedma; Carlos Juan; Joaquín R Otero; Antonio Oliver; Fernando Chaves
Journal:  Genome Announc       Date:  2013-04-11

10.  The RAST Server: rapid annotations using subsystems technology.

Authors:  Ramy K Aziz; Daniela Bartels; Aaron A Best; Matthew DeJongh; Terrence Disz; Robert A Edwards; Kevin Formsma; Svetlana Gerdes; Elizabeth M Glass; Michael Kubal; Folker Meyer; Gary J Olsen; Robert Olson; Andrei L Osterman; Ross A Overbeek; Leslie K McNeil; Daniel Paarmann; Tobias Paczian; Bruce Parrello; Gordon D Pusch; Claudia Reich; Rick Stevens; Olga Vassieva; Veronika Vonstein; Andreas Wilke; Olga Zagnitko
Journal:  BMC Genomics       Date:  2008-02-08       Impact factor: 3.969

View more
  1 in total

1.  Phylogenetic Distribution of CRISPR-Cas Systems in Antibiotic-Resistant Pseudomonas aeruginosa.

Authors:  Alex van Belkum; Leah B Soriaga; Matthew C LaFave; Srividya Akella; Jean-Baptiste Veyrieras; E Magda Barbu; Dee Shortridge; Bernadette Blanc; Gregory Hannum; Gilles Zambardi; Kristofer Miller; Mark C Enright; Nathalie Mugnier; Daniel Brami; Stéphane Schicklin; Martina Felderman; Ariel S Schwartz; Toby H Richardson; Todd C Peterson; Bolyn Hubby; Kyle C Cady
Journal:  mBio       Date:  2015-11-24       Impact factor: 7.867

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.